Saturday 17 October 2026
Export CLLS’s income statement to Excel — free account
Cellectis S.A.
CLLS Healthcare Biotechnology
Cellectis S.A.’s revenue for fiscal 2025 (year ended December 2025) was $79.6 million, up 61.7% from fiscal 2024. In the quarter to June 2026, revenue fell 62.1%, EPS grew 8.33%, free cash flow fell 37.0% and total debt was flat, each against the same quarter a year earlier.
1.04
0.07
−6.31%
Follow CLLS
Cellectis S.A. (CLLS) P/E ratio
Cellectis S.A. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 183× (May 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 183×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| EQ Equillium, Inc. compare | n/m |
| PTHS Pelthos Therapeutics Inc. compare | n/m |
| CLLS Cellectis S.A. | n/m |
| AARD Aardvark Therapeutics, Inc. compare | n/m |
| NMRA Neumora Therapeutics, Inc. compare | n/m |
| NTRB Nutriband Inc. compare | n/m |
| PMN Promis Neurosciences compare | n/m |
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)